samedan logo
 
 
 
spacer
home > ebr > autumn 2016 > in the genes
PUBLICATIONS
European Biopharmaceutical Review

In the Genes

Many people take pleasure in knowing that the phrase “D’oh” originates from the TV series ‘The Simpsons’, whereas those who really know smugly attribute it to Jimmy Finlayson from the Laurel and Hardy films of the 1920s and 1930s. In much the same way, many people think that stem cells and gene-editing are also new inventions. Indeed, if one were to anthropomorphise two of the newest biotechnology tools, most people would regard stem cell technology as a junior-school prodigy, and its younger brother, gene-editing, as a precocious preschooler.

This year, 2016, does indeed mark the tenth anniversary of the first description of pluripotent stem cells induced from mammalian adult fibroblast cultures by defined factors – and fewer than four years ago, a programmable, dual-RNA-guided DNA endonuclease called Cas9 caught the imagination of thousands of laboratories across the globe. Variants of these tools have enjoyed a long and successful history, winning Nobel prizes and saving lives long before their current incarnations were even a glint in their inventors’ eyes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Patrick Harrison is a Molecular Biologist at University College Cork, and his research is sponsored by the Cystic Fibrosis Trust. He began using gene-editing as a research tool for rare diseases in 2005, and his group was the first to publish a gene-editing strategy to correct the most common CF mutation in cells using ZFNs. His lab is currently using CRISPR-Cas9 and Cpf1 to study CF and other rare diseases, including cystinosis and epidermolysis bullosa.
spacer
Patrick Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England (PHE). The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.
More info >>

White Papers

Managing GxP Environmental Systems to Ensure Data Integrity

Vaisala Ltd


More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement